| 產(chǎn)品編號 | bs-8583R |
| 英文名稱 | phospho-IKKi (Ser172) Rabbit pAb |
| 中文名稱 | 磷酸化核因子NFκB抑制蛋白激酶i抗體 |
| 別 名 | IKKi/IKKe(phospho Ser172); p-IKKi(Ser172); p-IKKe(Ser172); IKKi/IKKe; I kappa B kinase epsilon; IkBKE; IKBKE protein; IKK E; IKK i; IKK-i; IKK related kinase epsilon; IKKE; IKK-E; IKKepsilon; IKKI; Inducible I kappa B kinase; inducible IkappaB kinase; Inhibitor of kappa light polypeptide gene enhancer in B cells kinase epsilon; Inhibitor of nuclear factor kappa B kinase subunit epsilon; KIAA0151; MGC125294; MGC125295; MGC125297; IKKE_HUMAN; I-kappa-B kinase epsilon; IKK-epsilon; Inducible I kappa-B kinase. |
| 產(chǎn)品類型 | 磷酸化抗體 |
| 研究領域 | 腫瘤 細胞生物 細胞凋亡 細胞周期蛋白 激酶和磷酸酶 表觀遺傳學 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human,Mouse,Rat (predicted: Rabbit,Pig,Cow,Dog) |
| 產(chǎn)品應用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 80 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞核 細胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human IKKi/IKKE around the phosphorylation site of Ser172: FV(p-S)VY |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
IKBKE is a noncanonical I-kappa-B (see MIM 164008) kinase (IKK) that is essential for regulating antiviral signaling pathways. IKBKE has also been identified as a breast cancer (MIM 114480) oncogene and is amplified and overexpressed in over 30% of breast carcinomas and breast cancer cell lines (Hutti et al., 2009 [PubMed 19481526]).[supplied by OMIM, Oct 2009]. Function: Phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. May play a special role in the immune response. Protects cells against DNA damage-induced cell death. Subunit: May interact with MAVS/IPS1. Interacts with AZI2. Interacts with SIKE1. Interacts with TICAM1/TRIF, IRF3 and DDX58/RIG-I, interactions are disrupted by the interaction between IKBKE and SIKE1. Interacts with TOPORS; induced by DNA damage. Interacts with CYLD. Subcellular Location: Cytoplasm. Nucleus. Nucleus > PML body. Targeting to PML nuclear bodies upon DNA damage is TOPORS-dependent. Tissue Specificity: Highly expressed in spleen followed by thymus, peripheral blood leukocytes, pancreas, placenta. Weakly expressed in lung, kidney, prostate, ovary and colon. Post-translational modifications: Autophosphorylated and phosphorylated by IKBKB/IKKB. Sumoylation by TOPORS upon DNA damage is required for protection of cells against DNA damage-induced cell death. Desumoylated by SENP1. Similarity: Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. I-kappa-B kinase subfamily. Contains 1 protein kinase domain. SWISS: Q14164 Gene ID: 9641 Database links: Entrez Gene: 9641 Human Omim: 605048 Human SwissProt: Q14164 Human Unigene: 321045 Human |
| 產(chǎn)品圖片 |
Sample:
Spleen (Mouse) Lysate at 40 ug
Thymus (Mouse) Lysate at 40 ug
Primary: Anti- phospho-IKKi (Ser172) (bs-8583R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 80 kD
Observed band size: 71 kD
Tissue/cell: rat lung tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-phospho-IKKi(Ser172) Polyclonal Antibody, Unconjugated(bs-8583R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
